BioLife Solutions (NASDAQ:BLFS) EVP Sells $16,902.90 in Stock

Key Points

• Aby Mathew, EVP of BioLife Solutions, sold 630 shares of the company's stock for approximately $16,902.90, reducing his ownership by 0.18% while retaining 351,421 shares valued at over $9.4 million.
• BioLife Solutions reported a loss of $0.33 per share for the latest quarter, significantly missing the expected loss of $0.02, although its revenue of $25.42 million exceeded forecasts.
• The stock has shown significant trading activity recently, with shares reaching $25.80 on Monday and a market capitalization of $1.24 billion, reflecting a 50-day moving average of $23.47.

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby Mathew sold 630 shares of the firm's stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $26.83, for a total transaction of $16,902.90. Following the completion of the sale, the executive vice president owned 351,421 shares of the company's stock, valued at $9,428,625.43. The trade was a 0.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

BioLife Solutions Price Performance

Shares of NASDAQ BLFS traded up $0.29 during mid-day trading on Monday, reaching $25.80. 403,794 shares of the company's stock traded hands, compared to its average volume of 478,382. The stock has a market cap of $1.24 billion, a P/E ratio of -214.98 and a beta of 1.78. The business has a 50-day simple moving average of $23.47 and a 200 day simple moving average of $23.29. BioLife Solutions, Inc. has a 1-year low of $19.10 and a 1-year high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). The business had revenue of $25.42 million for the quarter, compared to analyst estimates of $23.71 million. BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. BioLife Solutions has set its FY 2025 guidance at EPS. Equities research analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in BioLife Solutions in the fourth quarter valued at about $31,000. State of Wyoming increased its stake in shares of BioLife Solutions by 353.1% during the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock worth $44,000 after purchasing an additional 1,490 shares during the last quarter. US Bancorp DE raised its holdings in shares of BioLife Solutions by 243.7% in the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock worth $49,000 after purchasing an additional 1,528 shares during the period. Ameritas Investment Partners Inc. raised its holdings in shares of BioLife Solutions by 12.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider's stock worth $83,000 after purchasing an additional 441 shares during the period. Finally, GAMMA Investing LLC grew its holdings in BioLife Solutions by 18.6% during the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock valued at $96,000 after purchasing an additional 663 shares during the period. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BLFS. Stephens began coverage on shares of BioLife Solutions in a report on Tuesday, July 22nd. They set an "overweight" rating and a $30.00 price objective for the company. Zacks Research upgraded shares of BioLife Solutions to a "strong-buy" rating in a report on Monday, August 11th. HC Wainwright reiterated a "buy" rating and set a $32.00 price objective (up from $30.00) on shares of BioLife Solutions in a report on Friday, August 8th. Finally, Wall Street Zen cut shares of BioLife Solutions from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $31.29.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.